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1. Introduction 
Studies concerning the pathogenesis of atherosclerosis entered a new phase at the turn of 
the 21st century. The 20th century was the age of cholesterol and lipoproteins, which has 
been concluded in a number of clinical studies carried out on a large scale, and they 
demonstrated unequivocally that normalization of hypercholesterolemia significantly 
decreased the incidence and mortality of coronary artery disease (Prevention of 
cardiovascular events and death with pravastatin in patients with coronary heart disease 
and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin 
in Ischaemic Disease (LIPID) Study Group. 1998; Scandinavian Simvastatin Survival Study 
Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart 
disease: The Scandinavian Simvastatin Survival Study (4S). 1994)  Nearly to the end of the 
nineties, atherosclerosis had been assumed to develop as the so-called chronic response to 
injury (response-to-injury hypothesis) that resulted in the loss of endothelial cells which line 
the inner side of the vessels (Ross & Glomset, 1976).  
Atherosclerosis had been considered first of all a degenerative disease (Ross et al., 1977; 
Ross et al. 1984; Ross, 1986). However, approximately 20 years ago, the trials started to focus 
to a large extent on another pathogenetic mechanism of atherosclerosis, not considered so 
far – the inflammatory process. 
2. The first indications  
In 1986, with the use of monoclonal antibodies, the small cells with round nucleus present in 
the atheromatous plaque, known before as “small monocytes”, were demonstrated to be T 
lymphocytes (Jonasson et al., 1986). Several years later it was shown that these lymphocytes 
“recognize” as antigens the oxidized molecules of low-density lipoproteins (LDL) – oxLDL 
(Stemme et al., 1995). Moreover, the correlation between atherosclerosis and the presence of 
at least two types of infectious microorganisms: Chlamydia pneumoniae and Herpes simplex 
virus were observed (Thom et al., 1991; Hendrix et al., 1990). It raised the question if the 
inflammatory process participate in atherosclerosis. Speculations of this kind were initially 
received with great scepticism because there was no spectacular and unequivocal evidence 
of a significant role of inflammation in atherosclerosis. 
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This evidence was delivered by a new technique – gene targeting, for the invention of which 
Mario R. Capecchi (Italy), Martin J. Evans (United Kingdom) and Oliver Smithies (USA) 
received the Nobel Prize in Physiology or Medicine in 2007.  
3. Additional evidence for the presence of inflammation in atherosclerosis 
The newest model of atherosclerosis (described precisely at the end of the paper) enabled 
the investigators to create apoE-knockout mice, an ideal animal model to test the influence 
of singular proteins participating in the inflammatory response on the development of 
atherosclerosis. These studies showed, for example, that the absence of only one cytokine – 
interferon Ǆ (IFN-Ǆ), reduced atherosclerosis even by 60% (Gupta et al., 1997). 
The overexpression of adhesive molecules (vascular adhesion molecule 1 and intercellular 
adhesion molecule 1) at sites with atheromatous changes was also observed in 
apoE‑knockout mice (Nakashima et al., 1998). Monocyte chemotactic protein was shown to 
play an important part in the progression of atheromatous lesions (Aiello et al., 1999; Ni et 
al., 2001). Moreover, it was observed that interleukin-18 knockout decreased atherosclerosis 
by 35% (Elhage et al., 2003; Tenger et al., 2005). 
Inhibition of CD40 signaling reduced atherosclerosis (Mach et al., 1998). This was explained 
by the fact that ligation of CD40 molecule (tumor necrosis factor ǂ [TNF-ǂ] receptor 
superfamily member) – found in the atheromatous plaque, on endothelial cells, vascular 
smooth muscle cells, antigen-presenting cells, platelets – with CD40L activates a number of 
transcription factors: NF-κB, AP-1, STAT-1 or Egr-1. Therefore, it influences, for example, 
the endothelial cell, which, in consequence, acquires proinflammatory and 
proatherosclerotic phenotype leading to the expression of adhesive molecules and tissue 
factor on its surface. It creates new possibilities of therapeutic approach, consisting in 
inhibition of the CD40–CD40L pathway (Welt et al., 2004; Alber et al., 2006;  Tousoulis, et al. 
2007). In mice the effect of CD40 is also antagonized by transforming growth factor ǃ 
(Robertson et al., 2003). 
Finally, in apoE-knockout mice with severe combined immunodeficiency (SCID) 
atherosclerosis was reduced by 70% in comparison to the control group, due to a 
significantly lower number of lymphocytes in mice with SCID. It was demonstrated that 
transfer of T cells to these mice aggravated atherosclerosis even by 164% (Zhou et al., 
2000). 
4. Atherosclerosis as an inflammatory process 
These and other facts made the investigators realize unequivocally that inflammation was 
essential for atherogenesis. Therefore, in 1999, just before his death, Russell Ross (the author 
of the previous theory of atherosclerosis as a chronic response to injury) officially 
proclaimed that atherosclerosis was an inflammatory disease (Ross, 1999). 
Whereas the deposition of atheromatous lipids and the accumulation of foam cells – 
macrophages filled with such lipids – in intima is the main morphological hallmark of 
atherosclerosis, the more subtle changes in the environment of the arterial wall, stimulated 
by the influx of inflammatory cells and local release of cytokines and other inflammatory 
mediators are currently recognized as the crucial causative factors of atherogenesis (Glass & 
Witztum, 2001; Binder et al., 2002). 
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Inflammation occurs in response to a factor that destabilizes the local homeostasis. The 
factors that cause Toll-like receptor dependent macrophage activation in the arterial wall 
include oxLDL, heat shock protein 60 (HSP60) and bacterial toxins (Hansson, 2005). 
The first stage of atherogenesis consists in endothelial dysfunction (Ross, 1999). It 
involves first of all the regions of arterial bifurcations where the blood flow is not 
laminar. Hence, these localizations are prone to develop atherosclerosis. In such places 
LDL is stored in the subendothelial space. Low‑density lipoprotein accumulation is 
increased if serum LDL level is elevated. Low‑density lipoprotein is transported by 
passive diffusion and its accumulation in the vascular wall seems to depend on the 
interaction between apolipoprotein B of the LDL molecule and proteoglycans of the 
matrix (Boren et al., 1998). 
There is evidence that unchanged LDL are “collected” by the macrophages too slowly to 
activate their transformation into foam cells. Therefore, it has been suggested that LDL 
molecule is “modified” in the vascular wall. The most significant modification is lipid 
oxidation, resulting in the formation of so-called “minimally oxidized” LDL (Gaut & 
Heinecke, 2001). The generation of these “aliens” for the body molecules leads to the 
development of inflammatory response, with participation of monocytes and lymphocytes 
in the first place (Fredrikson et al., 2003; Pentikäinen et al., 2000). The inflammation is 
triggered by accumulation of the minimally oxidized LDLs in the subendothelial space, thus 
stimulating the endothelial cells to produce a number of proinflammatory molecules (Lusis, 
2000). 
Before the “minimally oxidized” LDL have been phagocytised by the macrophages, they 
have to be modified into “highly oxidized” LDL. The scavenger receptors are responsible for 
the rapid uptake of the modified LDL (Suzuki et al., 1997).  
During the following phase macrophages “present the antigen” to T lymphocytes. This 
antigen may be a fragment of oxidized LDL “digested” by the macrophages, HSP60, ǃ2-
glycoprotein I or the fragments of bacterial antigens (Hansson, 2001). The interaction 
between the immunological cells requires the presence of CD40 receptor on the surface of 
macrophages and its ligand CD40L on the surface of T lymphocytes (Schonbeck et al., 2000; 
Phipps et al., 2000). It is currently believed that the immunological response of Th1 type and 
its mediators: IFN-Ǆ, TNF-ǂ, interleukin-1, interleukin-12 as well as interleukin-18 accelerate 
atherosclerosis, whereas the response of Treg type and its mediators: interleukin-10 and 
TGF-ǃ inhibit the development of atherosclerosis (Daugherty & Rateri, 2002; Laurat et al., 
2001; Pinderski et al., 2002). Therefore, there has arisen an idea of vaccination as a future 
treatment against atherogenesis (Hansson, 2002). 
The next phase of atherogenesis is the development of fibrous atheroma. The deposition of 
extracellular cholesterol and its esters is then intensified as well as the migration of smooth 
muscle cells from media to intima, proliferation of these cells and finally production of the 
extracellular matrix by the smooth muscles cells. 
A stable atheromatous plaque is most commonly covered with a fairly thick fibrous layer, 
protecting the lipid nucleus from contact with the blood. In an unstable plaque there is a big 
lipid nucleus with a fairly thin fibrous layer. In atheromatous plaque, changed as described 
above, the proinflammatory factors produced by T lymphocytes (such as IFN-Ǆ) seem to 
play a crucial role. They decrease production of the extracellular matrix by smooth muscles 
and at the same time increase production of the metalloproteinases by macrophages 
(Shishehbor & Bhatt, 2004). 
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5. Is atherosclerosis an autoimmunological disease? 
The role of HSP60 as an initiator of atherogenesis is currently intensively investigated. Its 
“molecular mimicry” with HSP of Chlamydia has been observed (Wick et al., 1995). 
Moreover, the anti-oxLDL antibodies resemble antiphospholipid antibodies, therefore the 
concept of atherosclerosis as an autoimmunological disease has been established (Hansson, 
2001;  Kobayashi K et al., 2007; Wick G et al., 2001). The investigators also emphasize a high 
pathogenetic similarity of atherosclerosis to rheumatoid arthritis ( Shoenfeld et al., 2001). 
6. The new experimental model of atherosclerosis 
Since 1992 the mouse has become an excellent object for the studies on atherosclerosis, 
replacing the previous animal models. (Paigen et al., 1994; Moghadasian, 2002; Jawien et al., 
2004). 
Then, the first line of mice with a switched off gene for apolipoprotein E (apoE-knockout) 
was developed almost contemporaneously in two laboratories in the United States. 
(Piedrahita  et al., 1992; Plump et al., 1992). 
These mice were soon described as “reliable and useful, the best animal model of 
atherosclerosis in present times” (Meir & Leitersdorf, 2004). 
During the generation of apoE-knockout mice (known also as apoE null or apoE deficient 
mice) the normal gene coding apolipoprotein E is replaced by a mutated gene which does 
not produce this molecule. Such mice are called apoE knockout because they have a 
knockout, switched-off, null or inactivated gene coding apolipoprotein E. For clarity, in the 
following sections of this paper we will use the most popular name: apoE-knockout mice. 
The year 1992, in which apoE-knockout mice were invented by a homological exchange of 
genes, was a real breakthrough year in the studies on the pathogenesis of atherosclerosis 
(Savla, 2002). 
The apoE-knockout mice were formed by homological recombination of embryonic stem 
cells. The changed cells were implanted into the blastocyst of a mouse of C57BL/6J strain 
which were subsequently implanted into the uterus. The offspring was a “chimera” that was 
next crossbred with a mouse of C57BL/6J strain (wild type), which led to the formation of 
apoE-knockout, homozygous mice in the second generation (Capecchi, 2001). 
The inactivation of the gene coding apoE resulted in the formation of mice with a phenotype 
with a complete suppression of apoE, but with preservation of fertility and vitality (Breslow, 
1996). 
The apoE-knockout mice, in contrast to all of other animal models, develop atherosclerosis 
spontaneously, without high-cholesterol diet (Hansson et al., 2002). 
The generation of such a model changed the nature of the studies on the pathogenesis of 
atherosclerosis and enabled the investigators to formulate a new definition of 
atherosclerosis as a chronic inflammation (Savla, 2002). 
In a number of reports on atherogenesis published so far there has been a tendency to 
consider this process as the effect of dyslipidemia or inflammation alone. It is an erroneous 
dichotomy. It should be emphasized that atherosclerosis results from both lipid disorders 
and enhanced inflammation. Therefore, atherosclerosis is a chronic inflammatory disease, in 
most cases initiated and aggravated by hypercholesterolemia. In the review published in 
Nature Medicine hypercholesterolemia and inflammation were described as “partners in 
crime” (Steinberg, 2002). 
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The inflammatory concept of atherosclerosis has been formulated just in the recent years. 
However, it is currently an unquestionable achievement of science which also have specific 
therapeutic implications (Fan & Watanabe, 2003; Libby, 2000; Libby, 2002; Libby P et al., 
2002; Jawien et al., 2006; Alpert & Thygesen, 2007). 
7. Animal models of atherosclerosis 
Atherosclerotic cardiovascular disease, the major cause of death in Western society, results 
from complex interactions among multiple genetic and environmental factors.  
Numerous animal species have been used to study the pathogenesis and potential treatment 
of the lesions of atherosclerosis. The first evidence of experimental atherosclerosis came into 
view as early as in 1908 when Ignatowski (Ignatowski, 1908) reported thickening of the 
intima with formation of large clear cells in the aorta of rabbits fed with a diet rich in animal 
proteins (meat, milk, eggs). The most useful animal models have thus far been restricted to 
relatively large animals, such as nonhuman primates, swine, and rabbits. Hamsters and 
pigeons have been used occasionally but present problems peculiar to their species. Rats 
and dogs are not good models for atherosclerosis because they do not develop spontaneous 
lesions and require heavy modifications of diet to produce vascular lesion. Despite the fact 
that rabbits do not develop spontaneous atherosclerosis, they are useful because they are 
highly responsive to cholesterol manipulation and develop lesions in a fairly short time 
(Drobnik et al., 2000). 
The lesions are much more fatty and macrophage-rich (inflammatory) than the human 
lesions and plasma cholesterol levels are extraordinarily high (very dissimilar to humans). 
Pigs and monkeys are better suited to model human atherosclerotic lesions. However, 
nowadays monkeys are not widely used due to obvious species - specific concerns (risk of 
extinction) and cost. The pig is a very good model - when fed with cholesterol, they reach 
plasma levels and atherosclerotic lesions that are quite similar to those seen in humans. 
Problems with the pig model are costs, the difficulties involved in maintaining the colonies 
and in their handling.  
What has been traditionally lacking was a small, genetically reproducible, murine model of 
atherosclerosis. Such a model could help to overcome the many problems and deficiencies 
of larger animals and, in particular, would permit studies of possible therapies that require 
relatively large numbers of animals.  
Until 1992, the majority of atherosclerotic research focused on mechanisms in rabbits, with a 
lesser number of studies in pigs and nonhuman primates. These large animal models have 
provided invaluable insight. The use of pig models of the disease initially revealed that 
monocyte infiltration was one of the primary cellular events in the atherogenic process 
(Gerrity, 1981).  
Studies in monkeys and rabbits have been pivotal in defining the cellular events in the 
initiation and development of lesions (Faggiotto & Ross, 1984; Rosenfeld et al., 1987). In 
recent years, there has been an explosion in the number of in vivo studies that is largely 
attributable to the use of mouse models to study atherogenic mechanisms. 
8. Mouse as a model of atherosclerosis 
Mice are highly resistant to atherosclerosis. The only exception in mice is the C57BL/6 
strain. When fed a very high cholesterol diet containing cholic acid, however, the vascular 
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lesions in the C57BL/6 differ from the human condition in the histologic nature and location 
and are possibly attributed to a chronic inflammatory state rather than a genetic 
predisposition. 
The earliest mouse model of atherosclerosis was the diet - induced model that was first 
characterized during the 1960s in Wissler's laboratory. Special diet contained 30% fat, 5% 
cholesterol, and 2% cholic acid led to atherosclerosis in C57BL/6 mice. However, this was a 
very toxic diet on which the mice lost weight and often got sick with morbid respiratory 
infections. Paigen et al. modified this diet by blending it one part to three parts with a 10% 
fat diet to yield what is called the "Paigen diet" which consists of 15% fat, 1.25% cholesterol, 
and 0.5% cholic acid (Paigen et al., 1985). 
Although there were many uses of this model, there were also many disadvantages. The 
lesions are very small in mice at 4 to 5 months of age, in order of 200 to 1 000 square microns 
in the aortic root. The lesions are largely confined to the aortic root, and they usually do not 
develop beyond the early foam-cell, fatty-streak stage. The diet is also unphysiological with 
regard to its extremely high cholesterol content, 1.25%, and the presence of cholic acid. In 
addition, Lusis et al. have shown that this diet is in itself inflammatory, as leads to the 
induction of hepatic NF-kB activation and the expression of acute phase reactants, such as 
serum amyloid A (Liao et al., 1993). 
Paigen et al. colleagues also developed assays that are widely used to quantify 
atherosclerosis in the mouse model. The most standard assay is the measurement of the 
cross-sectional lesion area in the aortic root (Paigen et al., 1987). 
In this assay, freshly perfused and isolated hearts are fixed in formalin, embedded in gelatin, 
frozen, and cut into thin sections at anatomically defined sites in the aortic sinus and valve 
region. These sections are stained for lipids, and the lesion area is measured microscopically. 
Although this model has been widely employed and is of significant use in the study of 
atherosclerosis, the pathology of the lesions are not ideally suited as a model for human 
atherosclerosis. This shortcoming led many investigators to downplay the role of the mouse 
as a good model of atherosclerosis. Lesion formation in the diet - induced model is largely 
limited to the aortic root after feeding the Paigen - diet for periods of 14 weeks to 9 months. 
The lesions are quite small, only several hundred to a few thousand square micrometers, 
and they consist almost entirely of macrophage foam cells with little evidence for smooth 
muscle cell involvement. Thus, this model is largely limited to the fatty streak stage and 
does not progress to resemble human intermediate lesions.  
For many years the mouse was not used as an experimental model for atherosclerosis 
research because of the beliefs that mice could not survive on high - fat atherogenic diets, 
that lesions were not reproducible, that most mice did not get lesions, and that lesion 
pathology did not resemble atherosclerosis in humans. However, the use of lower - fat diets 
solved the survival problem; the use of inbred strains rather than random - bred mice solved 
the reproducibility problem; the use of susceptible strains resulted in most mice getting 
lesions; and longer experimental times showed that lesions with fibrous caps were 
produced. 
The following is a list of questions that can be used to judge the usefulness of animal models 
of atherosclerosis: 1) What is the nature of the experimental lesions and their similarity to 
human lesions; 2) is the plasma lipoprotein profile and metabolism similar to metabolism in 
humans; 3) what is the time frame necessary for lesions to form, and how long does it take 
to breed the animals for the studies; 4) what is the cost of acquiring and maintaining the 
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animals; 5) what is the ability to perform in vivo manipulations and imaging; and 6) what is 
the ability of the model to take advantage of classical and molecular genetic approaches ? 
The mouse as a model meets many of these criteria, but first it is important to acknowledge 
many important differences between mice and humans. The average lifespan of a mouse is 
about 2 years, compared to about 75 years in humans. Mice weigh much less, about 30 
grams for the adult. The lipid profile in the mouse is very different from that in humans, 
who carry about 75% of their plasma cholesterol on LDL. Mice carry most of their 
cholesterol on high-density lipoprotein (HDL), which we know in humans is protective 
against atherosclerosis. Thus, mice fed their normal low-fat chow diet do not get 
atherosclerosis, while it is a common disease in humans. One difference, which is an 
advantage of all animal models, is the ability to control the environment and diet in mouse 
studies, which is impossible for long-term human studies. Human genetic studies are 
limited in range to various types of association studies. With mice, on the other hand, many 
additional kinds of genetic experiments are possible, including breeding and genetic 
engineering. 
There are many advantages of using mice for experimental atherosclerosis research, 
including their relative ease and thriftiness to acquire and maintain. Their generation time is 
short, at about 9 weeks, 3 weeks for gestation and about 6 weeks until sexual maturity. It is 
easy to breed very large cohorts for experimental studies, and mice can develop 
atherosclerosis in a very short timeframe, as discussed below. Classical genetics in the 
mouse is very well established and is aided immensely by the availability of hundreds of 
inbred strains. Moreover, in 2002, The Mouse Genome Sequencing Consortium published 
the culmination of international efforts - a high quality sequence and analysis of the genome 
of the C57BL/6J mouse strain (Waterson et al., 2002). 
With the coming of age of molecular genetics, it is now possible to add exogenous 
transgenes into mice, which can also be done in many other species. However, uniquely in 
mice, it is also possible to knock out or replace endogenous genes; this is one of the main 
advantages of working in the mouse model. The major disadvantage of the mouse model is 
their small size, which makes it difficult but not impossible to perform surgical 
manipulations and in vivo imaging. But there have been recent advances in these techniques 
that have overcome many of the size limitations, such as the ability to perform imaging of 
abdominal atherosclerotic lesions in living mice, cardiac catheterization to determine 
cardiovascular function in free-ranging mice, and surgical ligature of coronary arteries 
giving rise to myocardial ischemia. 
9. Apolipoprotein E–knockout mice: A breakthrough 
It has been a longstanding goal of many investigators around the world to create better 
mouse models for lipoprotein disorders and atherosclerosis and to identify genes that may 
modify atherogenesis and lesion progression. In 1992 apoE - deficient mice were generated 
by inactivating the apoE gene by targeting (Piedrahita et al., 1992). 
They inactivated the apoE gene in mouse embryonic stem (ES) cells by homologous 
recombination. Two targeting plasmids were used, pJPB63 and pNMC109, both containing a 
neomycin-resistance gene that replaced a part of the apoE gene and disrupted its stucture. ES 
cell colonies targeted after electroporation with plasmids were identified by the polymerase 
chain reaction (PCR) followed by genomic Southern analysis. Chimeric mice were generated 
by blastocyst injection with targeted lines. They gave strong chimeras, which transmitted the 
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disrupted apoE gene to their progeny. Mice homozygous for the disrupted gene were 
produced from the heterozygotes. The facts that homozygous animals have been born at the 
expected frequency and that they appeared to be healthy were important. They demonstrated 
that lack of apoE was compatible with normal development, and they also provided another 
tool for studies of the phenotypic consequences of apoE deficiency. At the same time another 
group created also apoE - deficient mice (Plump et al., 1992). 
Mice homozygous or heterozygous for the disrupted apoE gene appeared healthy. No 
difference in their body weights compared to normal mice was observed. However, 
significant phenotypic differences between normal animals and the homozygous mutants 
were observed in their lipid and lipoprotein profiles. The apoE-knockout mice had 
markedly increased total plasma cholesterol levels, which were five times those of normal 
litter mates. These levels were unaffected by the age or sex of the animals. Although the 
total plasma cholesterol levels were greatly elevated in the mutants, the high density 
lipoprotein (HDL) cholesterol levels were only 45% the normal level. The triglyceride levels 
were 68% higher than those of normal animals. (These apoE-deficient mice have had a 
dramatic shift in plasma lipoproteins from HDL, the major lipoprotein in control mice, to 
cholesterol - enriched remnants of chylomicrons and VLDL. 
Mice naturally have high levels of HDL and low levels of LDL, in contrast to humans who 
are high in LDL and low in HDL. In addition, mice apparently lack the cholesteryl ester 
transfer protein, en enzyme that transfers cholesterol ester from HDL to VLDL and LDL. 
Despite these differences, apoE - deficient mice have phenotypes remarkably similar to 
those of apoE - deficient humans. 
A chronological analysis of atherosclerosis in the apoE - deficient mouse has shown that the 
sequential events involved in lesion formation in this model are strikingly similar to those in 
well - established larger animal models of atherosclerosis and in humans (Nakashima et al., 
1994). Animals as young as 5-6 weeks of age have monocytic adhesions to the endothelial 
surface of the aorta that can be appreciated readily with electron microscopy (EM). EM also 
has demonstrated transendothelial migration of blood monocytes in similarly aged mice. By 
6-10 weeks of age, most apoE - deficient mice have developed fatty - streak lesions 
comprised primarily of foam cells with migrating smooth muscle cells. These fatty - streak 
lesions rapidly progress to advanced lesions, which are heterogeneous but are typically 
comprised of a necrotic core surrounded by proliferating smooth muscle cells and varying 
amounts of extracellular matrix, including collagen and elastin.  
These lesions have well - formed fibrous caps made up of smooth muscle cells and 
extracellular matrix that often have groups of foam cells at their shoulders. It is not 
uncommon for the inflammatory lesion to erode deep into the medial wall of the aorta, and 
some of these animals develop aortic aneurysms. Many of the lesions found in older mice 
develop calcified foci (Reddick et al., 1994). 
Other characteristics of the lesions in the apoE - deficient mouse, such as indications of 
oxidative change, merit attention as well (Palinski et al., 1994). 
The atherosclerotic lesions in this mouse contain oxidation - specific epitopes. In young 
lesions these epitopes are predominantly localized in macrophage - rich areas, whereas in 
advanced lesions they are localized in necrotic regions. In addition, high titers of antibodies 
against the oxidized epitopes are present in the plasma of the apoE - deficient mice. 
The complexity of lesions in the apoE - deficient mouse, together with the benefits of using 
the mouse as a model of human disease, makes it a desirable system in which to study both 
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environmental and genetic determinants of atherosclerosis. Initial studies examined the 
effects of grossly different diets on susceptibility to atherosclerosis in this animal. These 
studies confirmed the validity of this mouse as a model of human atherosclerotic disease 
and laid the groundwork for future dietary studies. 
Hayek et al. developed a more physiological than Paigen diet - "western-type" diet for 
mouse studies, which is similar in composition to an average American diet of several years 
ago, consisting of 21% fat by weight, 0.15% cholesterol, and no cholic acid. When fed this 
diet, wild-type mice have a two-fold elevation in plasma cholesterol, while apoE-deficient 
mice have over a three-fold elevation, to about 2 000 mg/dl, again, mostly in ǃVLDL, but 
there is also an increase in LDL (Plump et al., 1992).  
The post-prandial clearance of intestinally derived lipoproteins is dramatically impaired in 
apoE - deficient mice. The apoE - deficient mouse responds appropriately to a human - like 
western - type diet (Nakashima et al., 1994). On this diet, lesion formation is greatly 
accelerated and lesion size is increased. In 10-week old animals fed this diet for only 5 
weeks, lesions are 3-4 times the size of those observed in mice fed a low - fat diet. In 
addition, monocytic adhesions and advanced lesions develop at a significantly earlier age. 
The results of this dietary challenge demonstrate that the mouse model responds in an 
appropriate manner, i.e. increased fat leads to increased plasma cholesterol, which in turn 
leads to increased atherosclerosis. Moreover, the data suggest that in addition to its 
histological similarity to humans, the mouse model exhibits a response to environmental 
cues resembling that of humans. 
Lesions in the apoE-deficient mouse, as in humans, tend to develop at vascular branch 
points and progress from foam cell stage to the fibroproliferative stage with well-defined 
fibrous caps and necrotic lipid cores, although plaque rupture has not been observed in 
apoE - deficient mice or in any other mouse model. Progression of lesions appears to occur 
at a faster rate than in humans atherosclerosis; the rapidity of lesion progression can be 
advantageous in many experimental situations. 
The genetic background has a major effect on atherosclerosis susceptibility in strains of apoE 
- deficient mice. For example, lesions from 16-week chow diet C57BL/6 apoE-KO were 
relatively larger than from FVB apoE-KO mice and in contrast to FVB mice there was 
evidence of early development of fibrous caps in these mice. In older mice, fibrous plaques 
from C57BL/6 apoE-KO mice were larger in size and had larger necrotic cores compared 
with FVB apoE-KO mice. Comparing humans and apoE - deficient mice, lesion progression 
and cell types are similar, as is the presence of oxidized lipoproteins. The major difference of 
this mouse model, as is the presence of oxidized lipoproteins. The major difference of this 
mouse model, as is the case for most of the other models of experimental atherosclerosis, is 
that plaque rupture is not observed, whereas plaque rupture is fairly common in humans 
and can lead to heart attacks. One potential reason for the lack of plaque rupture in mice is 
that the diameter of the aorta is less than 1 mm, which is even smaller than the diameter of 
the major coronary arteries in humans. As the vessel diameter decreases, the surface tension 
increases exponentially; thus, in the mouse there may be so much surface tension that 
plaque rupture would not be likely to occur. 
ApoE-knockout mice are considered to be one of the most relevant models for 
atherosclerosis since they are hypercholesterolemic and develop spontaneous arterial lesions 
(Nakashima et al., 1994). 
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Heterozygous apoE-deficient mice do not exhibit elevated plasma cholesterol levels on the 
chow or Western-type diet, suggesting that when mice are fed a physiological diet, a 50% 
decrease in apoE is not sufficient to influence fasting plasma lipids (Van Ree et al., 1994).  
The apoE-deficient mouse contained the entire spectrum of lesions observed during 
atherogenesis and was the first mouse model to develop lesions similar to those of humans. 
This model provided opportunity to study the pathogenesis and therapy of atherosclerosis 
in a small, genetically defined animal. 
In 1995 Kashyap et al. (Kashyap et al., 1995) described the successful correction of apoE 
deficiency in apoE-deficient mice by using an alternative approach involving systemic 
delivery to mouse liver of recombinant adenovirus vectors expressing human apoE. Thus, 
the single genetic lesion causing apoE absence and severe hypercholesterolemia is sufficient 
to convert the mouse from a species that is highly resistant to one that is highly susceptible 
to atherosclerosis (Breslow, 1994). 
The method of measure atherosclerosis by using the aortic root atherosclerosis assay was 
originally developed by Paigen et al. (Paigen et al., 1987). The aortic root cross sectioning 
assay is widely used in murine studies of atherosclerosis, allows for coincident inspection of 
lesion histology, and is amenable in studies using large numbers of mice. Alternative 
measures of atherosclerosis, such as the en face method, correlate with aortic root 
measurements. However, these methods are less amenable for studies using large numbers 
of mice and do not allow for inspection of lesion histology. 
10. LDL receptor deficient mice 
Gene targeting in embryonic stem cells has recently been used to create LDL receptor - 
knockout (LDLR-KO) mice, a model of familial hypercholesterolemia. LDL receptor - 
deficient mice was made in 1993 by Ishibashi et al. (Ishibashi et al.1993). These mice have a 
more modest lipoprotein abnormality than the apoE - deficient mice, with increases in LDL 
and VLDL cholesterol leading to a total plasma cholesterol of about 250 mg/dl on a chow 
diet. On this diet, and at that level of plasma cholesterol, LDL receptor - deficient mice do 
not get atherosclerosis. However, this is a very diet-responsive model. After these mice are 
fed the Paigen diet, their plasma cholesterol levels soar to about 1 500 mg/dl, and large 
atherosclerotic lesions form (Ishibashi et al., 1994). It has also been shown that feeding the 
less toxic western-type diet also leads to the development of large lesions, with plasma 
cholesterol levels of about 400 mg/dl. The lesion pathology in this model is not as well 
characterized as in the apoE - deficient model, but it does appear similar in that the lesions 
can progress beyond the foam - cell fatty-streak stage to the fibro-proliferative intermediate 
stage. 
11. Other mouse models 
Overexpression of human apoA-I in apoE - deficient mice increased HDL cholesterol levels 
twofold and substantially decreased fatty streak and advanced fibroproliferative lesion 
formation (Paszty et al. 1994; Plump et al., 1994). 
By 4 months of age, all but 3-5% of apoE - deficient mice have had detectable fatty streaks 
that vary considerably in size; some are barely detectable, whereas others occlude as much 
as 8% of the aortic lumen. In apoE - deficient mice that overexpress human apoA-I, more 
than 50% of animals have no lesions by 4 months of age, and the animals that do develop 
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atherosclerosis have lesions that are barley detectable. By 8 months of age, apoE - deficient 
mice have lesions that are highly organized and that occlude on average 25% of the aortic 
lumen. Those apoE - deficient mice that overexpress human apoA-I have mainly immature 
fatty - streak lesion that occlude on average only 5% of the aortic lumen. Collectively, these 
data suggest that overexpression of apoA-I can diminish lesion size and slow the initiation 
of fatty streak formation. 
More recently, apoE and LDL-receptor (LDLr) double – knockout (apoE/LDLr-DKO) mice 
have been created (Ishibashi et al., 1994), representing a new mouse model that develops 
severe hyperlipidaemia and atherosclerosis (Bonthu et al., 1997). 
It has been reported that, even on a regular chow diet, the progression of atherosclerosis is 
usually more marked in apoE/LDLr-DKO mice than in mice deficient for apoE alone 
(Witting et al., 1999).  
Thus,  the apoE/LDLr-DKO mouse is a suitable model in which to study the anti-
atherosclerotic effect of compounds without having to feed the animals an atherogenic diet. 
To study the contribution of endothelial nitric oxide synthase (eNOS) to lesion formation 
Kuhlencordt et al. (Kuhlencordt et al., 2001). created apoE / eNOS double - knockout mice. 
It has occured that chronic deficiency of eNOS increases atherosclerosis in apoE-KO mouse 
model. Furthermore, in the absence of eNOS, peripheral coronary disease, chronic 
myocardial ischemia, heart failure, and an array of vascular complications develop that have 
not been observed in apoE-KO animals. 
Recently, Veniant et al. (Veniant et al., 2000) managed to even up the cholesterol levels in 
chow-fed apoE-KO mice and LDLR-KO mice. They did so by making both mouse models 
homozygous for the apolipoprotein B-100 allele, which ameliorates the hypercholesterolemia 
in the setting of apoE deficiency but worsens it in the setting of LDLR deficiency. Moreover, 
the LDLR-KO Apob100/100 mice developed extensive atherosclerosis even on a chow diet. So 
far this model seems to be the best as concerns the development of atherosclerosis in mice. 
Therefore, gene - targeted mouse models has changed the face of atherosclerotic research 
(Savla U, 2002) and helped in creation of the new theory of atherosclerosis - as an 
inflammatory disease (Ross, 1999) 
12. The experimental use of gene targeted mice 
The apoE - deficient mouse model of atherosclerosis can then be used to: 1) identify 
atherosclerosis susceptibility modifying genes, by the candidate-gene and gene-mapping 
methods; 2) identify the role of various cell types in atherogenesis; 3) identify environmental 
factors affecting atherogenesis; and 4) assess therapies that might block atherogenesis or 
lesion progression. 
ApoE-deficient mice have also been used to look for environmental and drug effects on 
atherosclerosis and to test novel therapies. One of the first observations was paradoxical 
effects of probucol on atherogenesis in both apoE-KO (Moghadasian et al., 1999) and LDL 
receptor deficient (Bird et al., 1998) mice. Probucol with strong antioxidant and cholesterol - 
lowering effects increased atherogenesis in apoE-KO mice by 3 folds (Moghadasian et al., 
1999). Several other compounds reduced the extent and severity of atherosclerotic lesions 
without affecting plasma cholesterol levels in apoE–KO mice. For example, administration 
of antioxidant N,N'-diphenyl 1,4 - phenylenediamine (DPPD) to apoE-KO mice resulted in a 
significant decrease in atherosclerosis without reducing plasma cholesterol levels (Tangirala 
et al., 1995). 
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A marked reduction in atherosclerosis by dietary vitamin E was accompanied by no change 
in plasma cholesterol levels in apoE-KO mice (Pratico et al., 1998). 
Likewise, antiatherogenic effects of the angiotensin - converting enzyme inhibitors (Hayek 
et al. 1998; Keidar et al. 2000; Hayek et al. 1999) or the angiotensin II receptor antagonist 
(Keidar et al. 1997)  in apoE-KO mice were independent of plasma cholesterol lowering 
effects. 
Since inflammation plays an important role in atherogenesis, during recent years it has 
become apparent that the 5-lipoxygenase (5-LO) pathway may take significant part in 
modifying the pathogenesis of atherosclerosis. Enzymes associated with the 5-LO pathway 
are abundantly expressed in arterial walls of patients afflicted with various lesion stages of 
atherosclerosis of the aorta and of coronary arteries. These data raised the possibility that 
antileukotriene drugs may be an effective treatment regimen in atherosclerosis (Mehrabian 
et al., 2002). 
Of special interest for atherosclerosis is the arachidonate 5-LO which was originally 
identified in polymorphonuclear leukocytes, but which over-expression was recently 
demonstrated in macrophages, dendritic cells, foam cells, mast cells and neutrophils within 
atherosclerotic vessels. This enzyme generates an unstable epoxide intermediate compound 
leukotriene A4 (LTA4), which is an important precursor of LTB4, LTC4 and other cysteinyl 
leukotrienes. Initial observations and the use of drugs affecting the 5-LO metabolism were 
mainly connected with asthma and other inflammatory diseases (De Caterina & Zampolli, 
2004). 
However, a growing understanding of the role of inflammation in atherosclerosis has 
brought attention to the potential role of leukotrienes and their metabolism. In 2002 
Mehrabian et al. identified the 5-LO as a crucial enzyme, contributing to atherosclerosis 
susceptibility in mice (Mehrabian et al., 2002; Spanbroek et al., 2003). 
This observation, after a long pause (De Caterina R et al., 1988) has again focused the 
attention of researchers on the role of leukotrienes in the pathogenesis of atherosclerotic 
plaque (Radmark, 2003; Zhao & Funk, 2004; Zhao et al., 2004; Kuhn et al., 2005; Kuhn H, 
2005; Lotzer et al., 2005;  Back & Hansson, 2006; Radmark & Samuelsson, 2007). Therefore, 
the speculations have been risen that anti-asthmatic drugs could have beneficial effects on 
atherogenesis (Spanbroek &  Habenicht, 2003; Wickelgren, 2004; Funk, 2005; Back, 2006). 
Indeed, it has been recently demonstrated that the 5-LO substantially contribute to 
atherosclerosis in both mouse models and humans (Mehrabian & Allayee, 2003; Dwyer et 
al., 2004). Later Aiello et al. showed that LTB4 receptor antagonism reduced monocytic foam 
cells in mice (Aiello et al., 2002). Lotzer et al. pointed that macrophage-derived LTs 
differentially activate cysLT2-Rs via paracrine stimulation and cysLT1-Rs via autocrine and 
paracrine stimulation, during inflammation and atherogenesis (Lotzer et al., 2003). 
Therefore, a hypothesis has been formulated that leukotriene-inhibiting drugs developed to 
treat asthma might protect the heart. There are numerous potential targets that could be 
useful in the intervention in leukotriene metabolism in atherosclerosis. Interestingly, the 18 
kDa microsomal protein - five lipoxygenase activating protein (FLAP) was found to be 
critical for the regulation of 5-LO activity and biosynthesis of leukotrienes. The role of FLAP 
in atherosclerosis was additionally confirmed in humans by Helgadottir et al. (Helgadottir 
et al., 2004) who showed that genetic polymorphisms of FLAP are associated with 
myocardial infarction and stroke by increasing leukotriene production and inflammation in 
the arterial wall. 
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The 5-LO is abundantly expressed in atherosclerotic lesions of apoE and LDLR deficient 
mice, appearing to co-localize with a subset of macrophages but not with all macrophage-
staining regions. Indeed, the results of our studies showed that the inhibition of FLAP by 
MK-886 or BAYx1005 can significantly prevent the development of atherosclerosis in gene-
targeted apoE/LDLR-DKO mice ( Jawien et al., 2006; Jawien et al., 2007). 
Moreover, this study showed that cysteinyl leukotriene receptor blocker montelukast 
decreases atherosclerosis in apoE/LDLR-double knockout mice (Jawien et al., 2008). These 
results derived also from our numerous studies, concerned with atherosclerotic mice 
(Elhage et al., 2004; Elhage et al., 2005; Guzik et al., 2005; Jawien et al., 2005; Jawien et al., 
2007). 
The findings of the study concerning MK-886 were confirmed by Back et al. on their model 
of transgenic apoE-/- mice with the dominant negative transforming growth factor ǃ type II 
receptor, which displays aggravated atherosclerosis (Back et al, 2007). 
Colin D. Funk's research team questioned the hypothesis concerning leukotrienes, 5-LO and 
their role in atherogenesis in gene-targeted mice, stating that in mouse plaques there is no 5-
LO overexpression detectable (Cao et al., 2008). 
Finally, Poeckel & Funk in 2010, they tried to explain the whole complicated phenomenon. 
13. Limitations of animal models 
Animal models potentially bear the risk of compensatory mechanisms due to genetic 
modification of the target gene that render the results difficult to interpret. Another caveat is 
species differences between mice and humans. For instance, 5-LO expression in intimal 
atherosclerotic lesions varies between mice and humans; also, 5-LO and 12/15-LO appear to 
be differentially regulated in inflammatory cells of mice and humans with the murine 
12/15-LO producing mainly 12-HPETE, while its human counterpart primarily synthesizes 
15-HPETE. Notably, both products may have opposing effects in inflammation (Conrad DJ, 
1999). 
Moreover, atherogenesis in mice differs in several facets from the human pathology. Thus, T 
cells, whose presence in all stages of atherosclerotic lesions is acknowledged, are 
underrepresented in murine models of atherosclerosis (Daugherty & Hansson, as cited in 
Dean & Kelly, 2000; Roselaar et al., 1996). 
Despite these shortcomings, animal models afford an invaluable means to study the effects 
of directed genetic overexpression, deletion or pharmacological inhibition of key enzymes of 
the LT cascade in a physiological setting that cannot be achieved in humans. 
5-LO/LT pathway shows important disparities between murine and human atherosclerosis. 
Advanced human plaques show differences in 5-LO expression compared with mouse 
lesions. In human lesions, 5-LO (+) cells were identified in macrophages, DCs, mast cells, 
and neutrophils (Spanbroek et al, 2003) and notably, these 5-LO (+) cells are present in the 
neointimal region, whereas in mice, they are restricted to the adventitial layer (Zhao et al., 
2004). With increasing age, these adventitial macrophages form clusters with T cells, 
independent of the severity of atherosclerosis. Intimal inflammatory reactions are connected 
to distinct adventitial inflammation responses, whereby B lymphocytes, plasma cells, and T 
cells conglomerate with macrophages. 5-LO (+) cells accumulate around new blood vessels, 
a common feature between mice and humans.  
In human atherosclerotic plaque specimens, the quantity of 5-LO (+) cells even increased 
during progression from early to late phase coronary heart disease (Spanbroek et al., 2003). 
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Moreover, the elevated 5-LO activity was found to be associated with BLT1-mediated matrix 
metalloproteinase release from T cells, promoting plaque instability (Cipollone et al., 2005). 
Human lesions demonstrate detectable expression levels for all major components of the LT 
cascade, i.e., FLAP, LTA4 hydrolase, and LTC4 synthase, as well as BLT1/BLT2 and 
CysLT1/CysLT2 receptors. 
Taken together, in advanced human atherosclerosis, a role for 5-LO is likely, which is 
distinct from its role in early atherogenesis. This presence of the 5-LO/LT pathway in 
advanced lesions is not found in mouse models, which might be due to: (i) rapid 
progression of atheroma growth in mice vs. slower, often interrupted progression in 
humans (i.e., initial fatty streaks might remain dormant for many years in humans, until 
certain factors promote the progression of some lesions into an advanced state) (Libby, 2006; 
Libby & Sasiela, 2006)  (ii) advanced human plaques display a higher degree of instability 
and risk to rupture than murine plaques; (iii) temporal dissociation in the Th1/Th2 'balance' 
at distinct lesion stages between mice and humans (Kus et al., 2009; Toton-Zuranska et al., 
2010; Smith et al. 2010). 
14. Future directions 
During the last few years there has been a resurgent focus on the 5-LO/LT pathway as a 
potential target in coronary vascular disease (CVD). The complexity of the 5-LO/LT 
pathway participation in mechanisms contributing to CVD is evident based on the many 
studies (Poeckel & Funk, 2010). Limitations of these studies often result from the 'snapshot' 
punctual nature of analysing a single time point in CVD pathogenesis that makes it difficult 
to gain systematic insight into 5-LO-driven or -independent processes. 
Murine and human CVD etiology differ with respect to the 5-LO/LT pathway, and even 
within murine studies, the nature of the applied model (for atherosclerosis, abdominal aortic 
aneurysm (AAA), or ischemia/reperfusion injury) influences the conclusions. Whereas a 
role for 5-LO-derived LTs in early stages of murine and human atherosclerosis, AAA, and 
reperfusion injury is cogent based on their effects in chemotaxis and induction of pro-
inflammatory responses, the 5-LO pathway appears to play a distinct role in advanced 
human atherosclerosis, but not in advanced murine disease. Targeting specific leukotriene G 
protein-coupled receptors rather than upstream targets involved in LT synthesis may be a 
superior strategy for future CVD therapeutic interventions, based on extensive past 
experience with other pathways (e.g., via angiotensin II and adrenergic receptors), although 
this remains to be determined. Conditional knockouts and comprehensive translational 
studies should serve better than the traditional, simplistic 'one model' approach to 
understand the complex effects exerted by 5-LO products. Understanding the cytokine 
milieu during distinct stages of CVD progression will be crucial to elucidate how the 
expression of members of the 5-LO/LT pathway is regulated. There is little doubt that 5-LO 
plays important roles in many facets of CVD, but the challenge for future studies will be to 
clearly dissect these activities in a temporal and cell- and tissue- specific context in order to 
provide a solid basis for potential therapeutic interventions.  
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